The display of all BRCA2 germline and somatic mutations described in the curated set of non-redundant studies of cBioPortal for Cancer Genomics shows that BRCA2 is altered in 10–15% of breast, ovarian, and prostate cancer cases, whereas BRCA2 is altered in 18% of melanoma cases (Figure 4A). This evidence concerns the gene BRCA2 and prostate cancer.